CDRD, Canada’s national Centre for Drug Research and Development, is a global bridge that translates discoveries into innovative therapeutic products & improved health outcomes. In collaboration with our partners, we identify & advance promising discoveries & transform them into validated investments – all while uniquely training the next generation of highly-qualified personnel to drive the development of the innovations of tomorrow.
Scroll down to find out how we do this...
Identify & Evaluate
We proactively identify and evaluate
therapeutically promising and commercially relevant early-stage technologies within academia and Canadian life sciences companies.
Validate & Incubate
We replicate data, and build interdisciplinary
teams of experts to define and execute critical
experiments that will maximize probability of future clinical success and attract capital.
Accelerate & Commercialize
We generate valuable data around a technology, build a compelling business case and
comprehensive intellectual property package, and secure the private sector investors / partners to take the technology to patients.
May 30, 2018
CDRD will provide a portfolio of targeted antibodies and Schrödinger will apply its advanced computation platform in order to prioritize these drug candidates and otherwise accelerate discovery. The initial project will involve an immune checkpoint target that is present on cancer stem cells....Read MoreCDRD Further Builds Company Creation Team, Appoints Sacha...Read More
May 15, 2018
As an Entrepreneur-in-Residence, Sacha Mann will work with CDRD leadership to identify specific areas of strategic commercial opportunity, and then in partnership with other stakeholders, drive the building of a new company of scale that can develop those opportunities, and grow into a strong new anchor...Read MoreCDRD Appoints Dr. Lana Janes as Entrepreneur-in-ResidenceRead MoreCDRD & Schrödinger Announce Oncology Collaboration to...Read More
May 8, 2018
As an Entrepreneur-in-Residence, Dr. Janes will work with CDRD leadership to identify specific areas of strategic commercial opportunity, and then in partnership with other stakeholders, drive the building of a new company of scale that can develop those opportunities, and grow into a strong new anchor...Read MoreCDRD and Pfizer Canada Partner to Establish The CDRD Life...Read MoreCDRD Further Builds Company Creation Team, Appoints Sacha...Read More
May 2, 2018
CDRD and Pfizer Canada today announced the launch of the CDRD Executive Institute under the umbrella of The CDRD Academy. The Institute, made possible by a significant $1,000,000 contribution by Pfizer Canada, aims to provide ongoing executive development to ensure that the Canadian life sciences sector...Read MoreMS Society & CDRD Support Two New Translational...Read MoreCDRD Appoints Dr. Lana Janes as Entrepreneur-in-ResidenceRead More
March 20, 2018
CDRD, together with The MS Society, are overcoming challenges in the drug discovery pipeline by funding translational research. By tapping into the infrastructure and expertise in drug development and commercialization offered by CDRD, highly promising targets such as those being investigated by Dr. Granville and Dr....Read MoreZymeworks Advances Clinical Candidate Incorporating...Read MoreCDRD and Pfizer Canada Partner to Establish The CDRD Life...Read More
Zymeworks Advances Clinical Candidate Incorporating Technology Developed by CDRD Spin-Off Company Kairos TherapeuticsMarch 15, 2018
CDRD, Canada’s national drug development and commercialization centre, is pleased to share that “ZW49” by Zymeworks is the first product candidate selected for clinical development utilizing the ZymeLink™ antibody-drug conjugate (ADC) platform, acquired as part of the Company’s 2016 acquisition of Kairos Therapeutics. ZW49 was developed...Read MoreBudget 2018: A Platform for Scale and Focus in Canadian...Read MoreMS Society & CDRD Support Two New Translational...Read More
March 5, 2018
Canadian life sciences can lead the world – but we’re not there yet. The good news is we now have many of the tools to get there....Read MoreCDRD Announces Appointments to its Board of DirectorsRead MoreZymeworks Advances Clinical Candidate Incorporating...Read More
February 6, 2018
Today CDRD announced the appointment of Dr. Brad Popovich as Chair of its Board of Directors, Mr. Douglas Wilkes as Vice-Chair, and Dr. Laurence Rulleau as a new Director of the organization....Read MoreCDRD Appoints Dr. Rachael Ritchie Vice President, Strategy...Read MoreBudget 2018: A Platform for Scale and Focus in Canadian...Read More
November 16, 2017
As a developer and manager of large-scale, multi-partner, strategic partnerships, and interdisciplinary teams and projects, Dr. Ritchie will be responsible for the development and execution of CDRD’s corporate strategy, external R&D alliances, strategic scientific guidance for CDRD’s project portfolio, and will assume management responsibility for CDRD’s...Read MoreMerck & CDRD Announce Joint Investment in the Canadian...Read MoreCDRD Announces Appointments to its Board of DirectorsRead More
November 3, 2017
Merck & CDRD announced the establishment of a new $1.5M Merck-CDRD Innovation Fund. This fund will go directly towards the advancement of projects of high therapeutic potential carried out at CDRD in collaboration with academic researchers....Read MoreCDRD Appoints Dr. Rachael Ritchie Vice President, Strategy...Read More
See what else is new
Zucara is now moving forward with GLP toxicology, GMP manufacturing and other Investigational New Drug/Clinical Trial Application enabling activities to bring...Read the article
An experimental treatment for bladder cancer will move into an early phase clinical trial under an agreement between Cancer Research UK...Read the article
Outcomes with Impact
September 19, 2017
CDRD is committed to training the next generation of highly-qualified personnel to drive the development of innovations. Hear more about our unique Training Program and the opportunities it is creating from some of our young scientists…....Read MoreNovel therapies advancedRead More
August 24, 2017
CDRD has advanced 66 potential novel drug therapies towards the clinic. Many more are in production....Read MoreCommercial transactionsRead MoreTraining the Next GenerationRead More
August 11, 2017
CDRD has completed 14 commercial transactions including the merger of CDRD spin-off company, Kairos Therapeutics, with BC-based Zymeworks Inc. and creating one of Canada’s leading biotherapeutics companies....Read MoreSpin-off CompaniesRead MoreNovel therapies advancedRead More
August 11, 2017
CDRD has successfully created 7 spin-off companies including Kairos Therapeutics, Sitka Biopharma, Zucara Therapeutics, Precision Nanosystems, Immcure Therapeutics, Mesentech and Sepset Biopharma....Read MoreCommercial transactionsRead More
See what else is new
Working with CDRD
Academic discovery is the watering hole of innovation, but developing discoveries into new therapeutic products is a challenging process that requires complementary expertise, infrastructure and resources to that typically available to an investigator. That's where CDRD comes in.
Whether a company is looking to accelerate development of their lead program or strengthen their pipeline by pulling a secondary program off the back-burner, CDRD provides solutions for whatever scientific and/or commercial roadblocks are impeding progress towards the next corporate value-creation point.